Development, characterization, and in vitro evaluation of poly(ethylene oxide)-block-poly(ε-caprolactone)-α-tocopheryl succinate micelles as a novel nanocarrier for rapamycin delivery.

阅读:4
作者:Binkhathlan Ziyad, Alshememry Abdullah K, Balkhair Ahmad M, Ali Raisuddin, Alhudaithi Sulaiman S, Alobid Saad, Qamar Wajhul, Aodah Alhassan H, Vakili Mohammad Reza, Lavasanifar Afsaneh
Rapamycin holds significant therapeutic potential for various diseases; however, its clinical application is limited by several formulation challenges, primarily its extremely low aqueous solubility (2.6 μg/mL). To address this, nanoparticle-based delivery systems have emerged as a promising strategy to enhance solubility and enable sustained drug release. Currently, Fyarro® (Aadi Bioscience, Inc.), an albumin-bound nanoparticle formulation, is the only FDA-approved injectable rapamycin product. In this study, we aimed to develop and evaluate novel poly(ethylene oxide)-block-poly(ε-caprolactone)-α-tocopheryl succinate (PEO-b-PCL-α-TS) micelles and assess their potential as a delivery system for rapamycin. PEO-b-PCL copolymers with varying PCL/PEO ratios were prepared via ring-opening polymerization and modified by α-TS conjugation, as confirmed by (1)H NMR, GPC, XRD, DSC analyses. The optimum rapamycin-loaded micelles (PEO(2000)-b-PCL(4000)-α-TS) exhibited nano-sized particles (< 22 nm) with a narrow polydispersity index (<0.29), high drug encapsulation efficiency (≥92 %), and enhanced solubility (>1.3 mg/mL). Stability studies demonstrated that encapsulation protected rapamycin from degradation, maintaining over 90 % drug retention for three months at 4 °C, while in vitro release studies showed sustained release, with 50 % of rapamycin released from PEO(2000)-b-PCL(4000)-α-TS micelles over 72 h. In vitro cytotoxicity assays revealed anticancer activity against lung carcinoma epithelial cells (A549), and the human colon adenocarcinoma cell line (HCT116). Minimal toxicity (≥70 % viability) was observed in normal human fibroblast cells (HFF1). These results point to the potential of PEO-b-PCL-α-TS micelles as a promising nanocarrier system, offering improved rapamycin solubility, enhanced stability, sustained release, and effective anticancer activity.

特别声明

1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。

2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。

3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。

4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。